Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1948 3
1949 3
1950 4
1952 4
1953 2
1956 1
1957 1
1963 1
1965 2
1966 1
1967 3
1968 3
1970 4
1971 2
1972 1
1973 3
1974 2
1975 11
1976 7
1977 11
1978 12
1979 7
1980 11
1981 13
1982 13
1983 5
1984 11
1985 9
1986 12
1987 12
1988 3
1989 13
1990 16
1991 15
1992 16
1993 19
1994 17
1995 14
1996 20
1997 19
1998 18
1999 15
2000 25
2001 23
2002 23
2003 20
2004 22
2005 30
2006 33
2007 22
2008 40
2009 32
2010 24
2011 35
2012 36
2013 39
2014 40
2015 63
2016 37
2017 51
2018 73
2019 71
2020 74
2021 94
2022 89
2023 91
2024 89
2025 86
2026 73

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,583 results

Results by year

Filters applied: . Clear all
Page 1
Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections.
Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, Malinski C, Perkins R, Nasser M, Lopez C, Vittinghoff E, Buchbinder SP, Scott H, Charlebois ED, Havlir DV, Soge OO, Celum C; DoxyPEP Study Team. Luetkemeyer AF, et al. N Engl J Med. 2023 Apr 6;388(14):1296-1306. doi: 10.1056/NEJMoa2211934. N Engl J Med. 2023. PMID: 37018493 Free PMC article. Clinical Trial.
BACKGROUND: Interventions to reduce sexually transmitted infections (STIs) among men who have sex with men (MSM) are needed. METHODS: We conducted an open-label, randomized study involving MSM and transgender women who were taking preexposure prophylaxis (PrEP) against hum …
BACKGROUND: Interventions to reduce sexually transmitted infections (STIs) among men who have sex with men (MSM) are needed. METHODS: …
Neisseria gonorrhoeae physiology and pathogenesis.
Green LR, Cole J, Parga EFD, Shaw JG. Green LR, et al. Adv Microb Physiol. 2022;80:35-83. doi: 10.1016/bs.ampbs.2022.01.002. Epub 2022 Feb 18. Adv Microb Physiol. 2022. PMID: 35489793
Neisseria gonorrhoeae is an obligate human pathogen that is the cause of the sexually transmitted disease gonorrhoea. ...The gonococcus is able to subvert complement mediated killing and opsonisation by sialylation of its lipooligosaccharide and deploys a series of …
Neisseria gonorrhoeae is an obligate human pathogen that is the cause of the sexually transmitted disease gonorrhoea. ...The g …
Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
Ross JDC, Wilson J, Workowski KA, Taylor SN, Lewis DA, Gatsi S, Flight W, Scangarella-Oman NE, Jakielaszek C, Lythgoe D, Powell M, Janmohamed S, Absalon J, Perry C. Ross JDC, et al. Lancet. 2025 May 3;405(10489):1608-1620. doi: 10.1016/S0140-6736(25)00628-2. Epub 2025 Apr 14. Lancet. 2025. PMID: 40245902 Clinical Trial.
BACKGROUND: Gepotidacin, a first-in-class, bactericidal, triazaacenaphthylene antibacterial that inhibits bacterial DNA replication, was shown to be efficacious and well tolerated in the treatment of uncomplicated urinary tract infections. We evaluated the efficacy and saf …
BACKGROUND: Gepotidacin, a first-in-class, bactericidal, triazaacenaphthylene antibacterial that inhibits bacterial DNA replication, was sho …
Gonococcal arthritis.
Bardin T. Bardin T. Best Pract Res Clin Rheumatol. 2003 Apr;17(2):201-8. doi: 10.1016/s1521-6942(02)00125-0. Best Pract Res Clin Rheumatol. 2003. PMID: 12787521 Review.
Gonococcal arthritis results from blood dissemination of Neisseria gonorrhoeae from primary sexually acquired mucosal infection. The disease has become rare in Western countries since the introduction of effective control programmes, but it still needs to be …
Gonococcal arthritis results from blood dissemination of Neisseria gonorrhoeae from primary sexually acquired mucosal infec …
Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women.
Stewart J, Oware K, Donnell D, Violette LR, Odoyo J, Soge OO, Scoville CW, Omollo V, Mogaka FO, Sesay FA, McClelland RS, Spinelli M, Gandhi M, Bukusi EA, Baeten JM; dPEP Kenya Study Team. Stewart J, et al. N Engl J Med. 2023 Dec 21;389(25):2331-2340. doi: 10.1056/NEJMoa2304007. N Engl J Med. 2023. PMID: 38118022 Free PMC article. Clinical Trial.
BACKGROUND: Doxycycline postexposure prophylaxis (PEP) has been shown to prevent sexually transmitted infections (STIs) among cisgender men and transgender women, but data from trials involving cisgender women are lacking. METHODS: We conducted a randomized, open-label tri …
BACKGROUND: Doxycycline postexposure prophylaxis (PEP) has been shown to prevent sexually transmitted infections (STIs) among cisgend …
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 2 factorial design.
Molina JM, Bercot B, Assoumou L, Rubenstein E, Algarte-Genin M, Pialoux G, Katlama C, Surgers L, Bébéar C, Dupin N, Ouattara M, Slama L, Pavie J, Duvivier C, Loze B, Goldwirt L, Gibowski S, Ollivier M, Ghosn J, Costagliola D; ANRS 174 DOXYVAC Study Group. Molina JM, et al. Lancet Infect Dis. 2024 Oct;24(10):1093-1104. doi: 10.1016/S1473-3099(24)00236-6. Epub 2024 May 23. Lancet Infect Dis. 2024. PMID: 38797183 Clinical Trial.
BACKGROUND: Increased rates of sexually transmitted infections (STIs) are reported among men who have sex with men (MSM) and new interventions are needed. ...The incidence of a first episode of gonorrhoea, starting from month 3 was 58.3 per 100 person-years (103 eve …
BACKGROUND: Increased rates of sexually transmitted infections (STIs) are reported among men who have sex with men (MSM) and new inte …
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
Luckey A, Balasegaram M, Barbee LA, Batteiger TA, Broadhurst H, Cohen SE, Delany-Moretlwe S, de Vries HJC, Dionne JA, Gill K, Kenyon C, Kittiyaowamarn R, Lewis D, Mueller JP, Naicker V, O'Brien S, O'Donnell JP, Phanuphak N, Spooner E, Srinivasan S, Taylor SN, Unemo M, Zwane Z, Hook EW 3rd; Zoliflodacin Phase 3 Study Group. Luckey A, et al. Lancet. 2026 Jan 10;407(10524):147-160. doi: 10.1016/S0140-6736(25)01953-1. Epub 2025 Dec 11. Lancet. 2026. PMID: 41391465 Free PMC article. Clinical Trial.
BACKGROUND: Development of new treatments for gonorrhoea is a global public health priority. We aimed to evaluate the efficacy and safety of zoliflodacin versus ceftriaxone plus azithromycin in patients with uncomplicated urogenital gonorrhoea. ...Sites selected for …
BACKGROUND: Development of new treatments for gonorrhoea is a global public health priority. We aimed to evaluate the efficacy and sa …
Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension.
Luetkemeyer AF, Donnell D, Cohen SE, Dombrowski JC, Grabow C, Haser G, Brown C, Cannon C, Malinski C, Perkins R, Nasser M, Lopez C, Suchland RJ, Vittinghoff E, Buchbinder SP, Scott H, Charlebois ED, Havlir DV, Soge OO, Celum C. Luetkemeyer AF, et al. Lancet Infect Dis. 2025 Aug;25(8):873-883. doi: 10.1016/S1473-3099(25)00085-4. Epub 2025 Mar 24. Lancet Infect Dis. 2025. PMID: 40147465 Clinical Trial.
The independent endpoint adjudication committee was masked to group assignment. The primary outcome was presence of one or more bacterial STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, or early syphilis) each quarter. ...No serious adverse events were attribute …
The independent endpoint adjudication committee was masked to group assignment. The primary outcome was presence of one or more bacte …
Efficacy of Doxycycline as Preexposure and/or Postexposure Prophylaxis to Prevent Sexually Transmitted Diseases: A Systematic Review and Meta-Analysis.
Boschiero MN, Sansone NMS, Matos LR, Marson FAL. Boschiero MN, et al. Sex Transm Dis. 2025 Feb 1;52(2):65-72. doi: 10.1097/OLQ.0000000000002082. Epub 2024 Sep 24. Sex Transm Dis. 2025. PMID: 39316078
INTRODUCTION: Bacterial sexually transmitted infections (STIs), specifically infection by Chlamydia trachomatis , Neisseria gonorrhoeae , and Treponema pallidum , have an important burden worldwide. ...Hazard ratios (HRs) and risk ratios (RRs) with 95% confid …
INTRODUCTION: Bacterial sexually transmitted infections (STIs), specifically infection by Chlamydia trachomatis , Neisseria …
Performance of a single-use, rapid, point-of-care PCR device for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis: a cross-sectional study.
Morris SR, Bristow CC, Wierzbicki MR, Sarno M, Asbel L, French A, Gaydos CA, Hazan L, Mena L, Madhivanan P, Philip S, Schwartz S, Brown C, Styers D, Waymer T, Klausner JD. Morris SR, et al. Lancet Infect Dis. 2021 May;21(5):668-676. doi: 10.1016/S1473-3099(20)30734-9. Epub 2020 Nov 23. Lancet Infect Dis. 2021. PMID: 33242473 Free PMC article.
If the results of those assays did not match, the BD MAX CT/GC/TV was used as a tiebreaker. The primary outcomes were the sensitivity and specificity of the investigational device for the detection of C trachomatis, N gonorrhoeae, and T vaginalis compared with patie …
If the results of those assays did not match, the BD MAX CT/GC/TV was used as a tiebreaker. The primary outcomes were the sensitivity …
1,583 results